Erika Rijavec

机构：Varian Medical Systems (United States)

发表论文 1 篇

代表论文

• EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the ‘Rebiopsy on osi’ Study) (2026 · The Oncologist)